Kanał CYBN
CY

Cybin Inc.

CYBN · AMEX

$8.28 +1.22% (+$0.10)
Piotroski F-Score Weak
0/9
Valuation
-
N/A
P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
-
N/A
ROIC N/A
ROE N/A
ROA N/A
Debt
-
N/A
Debt/Equity N/A
Current ratio N/A
Int. coverage N/A
Stability
100 /100
Stable
Beta 0.79x
Rev. volatility N/A
EPS volatility N/A

Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej

Zapytaj StockBota o CYBN
Online

O spółce

Cybin Inc. (CYBN) is a biotechnology company specializing in the development of therapeutic therapies based on psychedelic compounds for the treatment of various mental disorders. The company focuses on developing medications that utilize psychedelic substances such as psilocybin to support the treatment of conditions like depression, anxiety disorders, and post-traumatic stress disorder. Cybin Inc. is engaged in clinical studies and research to provide new treatment options for patients suffering from mental illnesses. With the growing interest in alternative therapeutic approaches in the field of mental health, Cybin Inc. has the potential for sustained growth. Cybin Inc. (CYBN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies based on psychedelic compounds industry.

Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.

Sector

Healthcare

Industry

Biotechnology

CEO

Eric So

Employees

50

Headquarters

Toronto

Używamy niezbędnych plików cookie do działania strony oraz opcjonalnych analitycznych plików cookie do pomiaru ruchu. Zobacz naszą Politykę prywatności.